Insofar as schizophrenia is a neuropsychiatric syndrome involving the brain, neuropathology is a promising, if not essential investigative approach. Although traditional neuropathology has yet to yield a pathognomonic lesion in schizophrenia, there have been no shortages of findings. Unfortunately, many of these findings have not only failed to be pathognomonic, but they have not been consistently replicated. Fortunately, newer neuropathological techniques, such as post-mortem neurochemistry, have resulted in findings among the most reproducible in schizophrenia research. Although one of these, increased dopamine receptors in the basal ganglia of schizophrenic patients, has been replicated many times, it suffers from doubts as to its clinical relevance. Are these increases in dopamine receptors primary to the illness or a side effect of the treatment? This article discusses the relevance of this finding, reviews other highlights of postmortem neurochemistry and traditional neuropathology, and discusses new horizons such as autoradiography, immunocytochemistry, and neuronal morphometrics.
Post-mortem Neurochemistry
Basal Ganglia (Caudate, Putamen, and Clobus Pallidus). Probably the most reproducible neuropathological finding in the schizophrenic syndrome to date is that of increased numbers of dopamine type II (D 2 ) receptors (which are neither linked to nor responsible for a decrease in adenylate cyclase activity) in the caudate and putamen (see table 1 ). Insofar as neuroleprics are thought to exert their therapeutic effect by D 2 blockade (Creese et al. 1976) , this finding may explain some of the psychopathology of the schizophrenic syndrome. Unfortunately, the vast majority of subjects studied to date have received neuroleptic treatment, which can increase D 2 receptors by virtue of a denervation supersensitivity effect (Clow et al. 1980; Murugaiah et al. 1984) . For a more detailed discussion of post-mortem studies of dopamine receptors in schizophrenia, a recent review is available (Jaskiw and Kleinman, in press). Attempts to resolve this conundrum with "in vivo" positron emission tomography of D 2 receptors in drug-naive schizophrenic patients have yielded conflicting results (Wong et al. 1986; Farde et al. 1987 ).
The second form of dopamine receptor, type I (D : ) receptors (those linked to an increase in adenylate cyclase activity), has been studied far less. Although several studies have failed to find any differences between patients and controls (Carenzi et al. 1975; Cross et al. 1981; Pimoule et al. 1985) , one report has found increased responsiveness of Dj receptors in caudate nuclei of schizophrenic patients (Memo et al. 1983) . Unfortunately, this finding has not been replicated, and a neuroleptic effect has not been excluded. The finding received some support from one binding study of D t receptors in which reduced dissociation constants (indicating increased affinity) were reported (Hess et al. 1987) . Interestingly enough, this is the (Cross et al. 1981 , Pimoule et al. 1985 Although a number of other receptors, neurotransmitters, metabolites, neuromodulators, and enzymes have been studied in schizophrenic brains, the only replicable finding has been increased serotonin in the putamen (Crow et al. 1979; Korpi et al 1986) and globus pallidus (Farley et al 1980; Korpi et al. 1986 ) A more detailed review of this topic is available elsewhere (Jaskiw and Kleinman, in press) Limbic System (Nucleus Accumbens, Hypothalamus, Amygdala, Ventral Septum, Mammillary Bodies, Bed Nucleus of the Stria Terminalis and Olfactory Area). Increases in both D, (Memo et al 1983) and D 2 (Lee et al 1978 , Owen et al. 1978 Lee and Seeman 1980; Seeman et al 1984) receptors have been reported in the nucleus accumbens Unfortunately, the controversy as to the significance of these findings is not much different than that seen in the basal ganglia.
A second finding, increased norepinephnne concentration in the nucleus accumbens of chronic paranoid schizophrenic patients (Farley et al. 1978 , Kleinman et al 1982 , has not been seen in studies which fail to examine schizophrenic subtypes (Bird et al 1979 , Crow et al 1979 . Moreover, a concomitant increase in a major norepinephnne metabolite, 3 methoxy-4-hydroxyphenylglycol was reported in one of the positive studies (Kleinman et al 1982) Lastly, increases in norepinephnne concentrations have been observed in several other limbic structures (Farley et al 1978) Insofar as these findings (especially in the nucleus accumbens) have not been seen in treated undifferentiated schizophrenic patients (Kleinman et al 1982) , the increased norepinephnne concentrations found in paranoid patients may not be a neuroleptic effect A third intriguing finding involves increased dopamine (Reynolds 1983, Reynolds and Czudek 1986) and homovanillic acid (a major dopamine metabolite) concentrations (Reynolds and Czudek 1986) in the left amygdala. Failures to replicate this finding have involved comparisons where both Note -• = increased, • = decreased FCx = frontal cortex PFCx = prefrontal cortex GLU = glutamate BA = Brodmann area TRH = thyrotropin-releasing hormone SRIF = somatostatm CCK = cholecystokinin 5HT = serotonin KA = kainic acid GABA = 7 -<aminobutync acid the left and right amygdala were not from the same subject. Since dopamine and homovanillic acid are both unstable post-mortem, comparisons of left and right nuclei from the same subject reduce the variability and enhance the opportunity to see neurochemical differences. This finding deserves an attempt at replication with the same methodology in other laboratories.
Cerebral Cortex. Despite the size and importance of the cerebral cortex in the human brain, there have been relatively few studies (for a review, see Jaskiw and Kleinman, in press) and still fewer positive findings (see table 2 ). This is regrettable as the cerebral cortex is worthy of study in schizophrenia for a number of reasons some of which are described in detail elsewhere (Weinberger and Berman, this issue). Moreover, the cortex is a major innervator and regulator of the basal ganglia (Carpenter and Sutin 1983) with the potential to regulate and increase D 2 receptors (Pycock et al. 1980) . Perhaps, the difficulties in dissecting cerebral cortex may account for the paucity of studies in this particularly "human" part of the brain.
Brainstem and Other Areas.
Although the source of many of the catecholamines and indoleamines in the basal ganglia, limbic system, and cerebral cortex is the brainstem and related structures, these latter areas have been infrequently investigated in postmortem neurochemistry. Of special interest are reports of increased D 2 receptors in substantia nigra ) and increased norepinephrine concentrations in the pons (Carlsson et al. 1980) . Obviously, more work needs to be done in this area. A more extensive review is available elsewhere (Jaskiw and Kleinman, in press).
Traditional Neuropathology
Basal Ganglia. Unlike the neurochemistry of the basal ganglia, there are no consistent neuropathological changes in these nuclei. Some of the more promising findings over the last several decades have focused on the globus pallidus of catatonic patients as summarized in table 3. As a major route of exit from the caudate and putamen, the globus pallidus deserves further study in relation to post-mortem neurochemical findings in schizophrenia.
Limbic System. Two groups of neuropathological changes have been reported in the limbic system in schizophrenic patients: gliosis in the hypothalamus (Nieto and Escobar 1972; Stevens 1982) and hippocampal structural abnormalities (Bogerts et al. 1985) . Diffuse gliosis has been reported in peri- Southard (1914 , 1915 , 1919 ) Vogt and Vogt (1952 Coin ( 1972; Stevens 1982 ). An attempt to confirm these findings using glial fibrillary acidic protein as a measure was unsuccessful (Casanova et al. 1987 ) Whether this technique is a reliable measure of gliosis, however, is itself debatable (Roberts et al 1986 (Roberts et al , 1987a Casanova et al. 1987) . Further attempts to replicate these findings and to determine their significance are obviously needed. A second promising series of studies of the hippocampus has emerged over the last decade The highlights of these studies involve reports of disarray of hippocampal pyramidal cells (Scheibel and Kovelman 1981; Kovelman and Scheibel 1984) and reduced hippocampal volume (Bogerts et al. 1985) . Unfortunately, the former was not replicated using a different staining technique (Weinberger et al 1980; Altshuler et al. 1987; Christison et al 1988) . Reduced hippocampal volume has not yet been replicated or refuted, but the finding also includes the amygdala and the hippocampal formation (Bogerts et al 1985) , an area where another study had similar findings (Brown et al 1986 One finding of brain "pathology," ventriculomegaly, has been reported in numerous computed tomographic brain studies (Shelton and Weinberger 1986) . Although edema obliterates ventricles acutely post-mortem, a satisfactory assessment can be made after standard fixation (Pakkenberg 1987) To date, several post-mortem studies have confirmed ventriculomegaly in schizophrenic patients, especially in association with deficit symptoms (Pearlson et al 1984; Williams et al 1985) .
New Approaches
The inability of traditional neuropathology and post-mortem neurochemistry to unravel the mysteries of schizophrenia suggest the need for new approaches Fortunately, autoradiography, immunocytochemistry, and neuronal morphometrics are now available as new techniques in neuropathology. Thus far, they have been applied only rarely in schizophrenic research (Ko et al. 1986 ) Difficulties in dissecting small nuclei and poorly defined structures, as well as the magnitude of the problem (billions of neurons), make these approaches attractive. They offer some hope for an answer to the simple question Where to look?
Discussion
Perhaps the single most significant post-mortem neurochemical study to date has been the discovery that there is reduced dopamine in the caudate and putamen of patients with Parkinson's disease (Ehringer and Hornykiewicz 1960) This finding ultimately led to a major treatment for this syndrome, namely, Ldopa. Insofar as this is a model for post-mortem neurochemical studies, it is probably worthwhile to remember that pigment loss of the substantia nigra gave a valuable clue as to where one should look
The question that arises is whether there are any similar clues in the dozens of post-mortem studies reviewed to date. Although there is clearly no pathognomonic lesion, the most replicable findings to date involve D 2 receptor increases. Although it is unclear whether this "finding" is primary to the syndrome or a byproduct of treatment, it is, at the least, suggestive that the basal ganglia (caudate, putamen) and nucleus accumbens" are one place to look It seems unlikely that schizophrenia is "|ust" a basal ganglia or nucleus accumbens disorder But if these structures are involved, then perhaps their connections are important The afferents to the caudate and putamen include the cerebral cortex, amygdala, substantia nigra, ventral tegmentum, and the thalamus. The efferents include the globus pallidus, substantia nigra, and cerebral cortex Perhaps the way to proceed with further neuropathological studies is to study the input and the output of the basal ganglia with the new techniques of autoradiography, immunocytochemistry, and neuronal morphometrics We hope that this approach will teach us something about the regulation of dopamine receptors and the significance of increases in these receptors in schizophrenic brains. 
